Nomura Holdings Inc. lowered its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 10.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 70,073 shares of the biopharmaceutical company's stock after selling 7,939 shares during the quarter. Nomura Holdings Inc.'s holdings in Ultragenyx Pharmaceutical were worth $2,901,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. Lazard Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 36.6% during the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 240 shares during the period. Chartwell Investment Partners LLC raised its stake in shares of Ultragenyx Pharmaceutical by 3.6% during the 3rd quarter. Chartwell Investment Partners LLC now owns 7,623 shares of the biopharmaceutical company's stock worth $316,000 after purchasing an additional 268 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Ultragenyx Pharmaceutical by 7.6% during the 2nd quarter. Virtus ETF Advisers LLC now owns 4,895 shares of the biopharmaceutical company's stock worth $292,000 after purchasing an additional 345 shares during the period. Signaturefd LLC raised its stake in Ultragenyx Pharmaceutical by 151.0% in the 3rd quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 361 shares during the period. Finally, Treasurer of the State of North Carolina raised its stake in Ultragenyx Pharmaceutical by 1.3% in the 3rd quarter. Treasurer of the State of North Carolina now owns 28,613 shares of the biopharmaceutical company's stock valued at $1,185,000 after acquiring an additional 370 shares during the period. 93.17% of the stock is currently owned by institutional investors.
Get Ultragenyx Pharmaceutical alerts:Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on RARE shares. Canaccord Genuity Group restated a "buy" rating and issued a $90.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 18th. Robert W. Baird boosted their price objective on Ultragenyx Pharmaceutical from $50.00 to $57.00 and gave the company an "outperform" rating in a research note on Friday, February 17th. HC Wainwright restated a "buy" rating and issued a $82.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 30th. Morgan Stanley lowered their price objective on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an "overweight" rating on the stock in a research note on Friday, February 3rd. Finally, Credit Suisse Group restated an "outperform" rating and issued a $96.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 17th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $89.47.
Ultragenyx Pharmaceutical Trading Down 2.9 %
Shares of NASDAQ RARE opened at $38.76 on Friday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $33.36 and a 12 month high of $85.53. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of -3.83 and a beta of 0.94. The business has a 50-day moving average of $44.32 and a 200-day moving average of $42.39.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last issued its quarterly earnings data on Thursday, February 16th. The biopharmaceutical company reported ($2.16) EPS for the quarter, missing the consensus estimate of ($2.03) by ($0.13). Ultragenyx Pharmaceutical had a negative return on equity of 110.15% and a negative net margin of 194.71%. The business had revenue of $103.35 million for the quarter, compared to analysts' expectations of $105.11 million. During the same period in the previous year, the firm posted ($1.79) EPS. The firm's revenue for the quarter was up 23.9% compared to the same quarter last year. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.62 earnings per share for the current year.
Insider Transactions at Ultragenyx Pharmaceutical
In other news, CAO Theodore Alan Huizenga sold 639 shares of the business's stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $43.40, for a total transaction of $27,732.60. Following the completion of the transaction, the chief accounting officer now owns 15,558 shares of the company's stock, valued at $675,217.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, EVP Camille L. Bedrosian sold 3,881 shares of the company's stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $45.25, for a total value of $175,615.25. Following the completion of the sale, the executive vice president now owns 46,720 shares of the company's stock, valued at $2,114,080. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Theodore Alan Huizenga sold 639 shares of the company's stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $43.40, for a total value of $27,732.60. Following the completion of the sale, the chief accounting officer now directly owns 15,558 shares of the company's stock, valued at approximately $675,217.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,940 shares of company stock valued at $310,388. 6.70% of the stock is owned by corporate insiders.
Ultragenyx Pharmaceutical Company Profile
(Get Rating)
Ultragenyx Pharmaceutical, Inc engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Recommended Stories
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.